One of the paused trials was called PBTC-059. A Phase 1 trial led by researchers at Texas Children’s Hospital in Houston, it was exploring the safety of CAR-T therapy in patients with a rare brain cancer called ependymoma. The therapy, in which a patient’s blood is engineered to boost its immune response, has generated huge excitement in the pediatric brain cancer community. CAR-T therapy has dramatically improved cure rates for the most common childhood leukemia.
Another trial, called PBTC-N14, was closed entirely. The first step after a brain-tumor diagnosis is often a brain biopsy, but these are invasive. Consortium researchers at Memorial Sloan Kettering were exploring whether cerebral spinal fluid, collected without surgery, might provide the same genetic information and help guide treatment while sparing children harm. “Everyone thought it was a good study, and tried to answer a good question,” its lead investigator, Matthias Karajannis, told me. “But it did not finish answering that question.”
The consortium ended in September 2026, with the weekly video meeting. It had a funereal tone, Dunkel said.
The shuttering was “one of the very worst professional moments of my career,” Dunkel told me. “I felt the loss of hope and opportunity for the parents and the patients. The loss of progress in the field for everyone involved, the doctors and scientists as well as the patients.”
“I guess I never really thought that this was my fault,” he said, then paused. “But I did feel like as the captain of the ship, I let down a lot of people.”
In late August 2025, Keith Desserich received a call from Dunkel, who relayed the news. “I think he was on the verge of tears,” Desserich told me.
Together with his wife, Brooke, Desserich founded The Cure Starts Now in 2007 after the death of their 6-year-old daughter, Elena, to D.I.P.G. The families who volunteer with The Cure Starts Now, most who have had a child die from a brain tumor, collect donations by hosting 5K runs and bowling nights and direct the funds toward promising, early-stage research.